PaySign, Inc.

PaySign, Inc. Earnings Recaps

PAYS Industrials 2 recaps
Next earnings: March 23, 2027 (estimated) · full calendar
Q3 2026 Nov 14, 2026

PaySign shares fell 18.9% after earnings, with the planned loss of payment processing at 113 plasma centers likely weighing on investors despite rapid patient-affordability growth. The transition is expected to be completed in Q4, and management said it expects new centers to offset the loss over the next couple of quarters.

Key takeaways
  • Revenue rose 43% year over year to $30.8 million; net income increased more than 200% to $6.7 million, or $0.11 per diluted share.
  • Patient-affordability revenue more than doubled to $16.6 million, with claim volume up approximately 55%; revenue per program rose about 32% to $99,500.
  • Gross margin expanded 840 basis points to 64.7%, as patient affordability became a larger share of revenue.
  • PaySign launched 19 programs in Q3 and had 167 active programs; it expects to end 2026 with 190–195.
  • Plasma revenue increased 7.5% to $13.8 million, but the company expects to end the year with 445–450 centers, down from 562 at quarter-end, following the customer transition.
Q1 2026 May 14, 2026

Shares plunged 12.9% as investors reacted negatively to the company’s cautious outlook and operational headwinds despite reported revenue growth. The disconnect likely stems from Q1 being described as “operationally constrained” and uncertainty around the impact of center closures in the plasma business.

Key takeaways
  • Revenue increased 50.8% year-over-year to $28 million, driven primarily by an 82% rise in the patient affordability segment to $15.7 million.
  • Operating margins expanded by 10.4 percentage points year-over-year, reflecting some operating leverage.
  • Patient affordability claim volume grew 49% versus Q1 2025, with $540 million in financial assistance provided to patients (up from $320 million).
  • Plasma donor revenue rose 25% to $11.7 million but faced headwinds from the closure of 19 low-performing centers and a net decline of 22 centers compared to end-2025.
  • Management highlighted that Q1 is typically a constrained period due to plan year renewals and formulary changes, suggesting potential near-term deceleration and pressure on growth visibility.